A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. per Evers, B, Schut, E, van der Burg, E, Braumuller, T, Egan, D, Holstege, H, Edser, P, Adams, D, Wade-Martins, R, Bouwman, P, Jonkers, J

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers per Zingg, D, Bhin, J, Yemelyanenko, J, Kas, SM, Rolfs, F, Lutz, C, Lee, JK, Klarenbeek, S, Silverman, IM, Annunziato, S, Chan, CS, Piersma, SR, Eijkman, T, Badoux, M, Gogola, E, Siteur, B, Sprengers, J, de Klein, B, de Goeij-de Haas, RR, Riedlinger, GM, Ke, H, Madison, R, Drenth, AP, van der Burg, E, Schut, E, Henneman, L, van Miltenburg, MH, Proost, N, Zhen, H, Wientjens, E, de Bruijn, R, de Ruiter, JR, Boon, U, de Korte-Grimmerink, R, van Gerwen, B, Féliz, L, Abou-Alfa, GK, Ross, JS, van de Ven, M, Rottenberg, S, Cuppen, E, Chessex, AV, Ali, SM, Burn, TC, Jimenez, CR, Ganesan, S, Wessels, LFA, Jonkers, J